Flociprin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flociprin

Property Description
Active ingredient Ciprofloxacin
Form Tablet, Oral Suspension, Injection, Eye/Ear Drops
Pharmacological class Fluoroquinolone Antibiotic
General purpose Eliminates susceptible bacteria
Origin Synthetic (Chemically manufactured)

Flociprin is a synthetic medicine whose active ingredient is Ciprofloxacin, a key member of the fluoroquinolone antibiotic class. This medication is designed to fight infections caused by susceptible bacteria and is available strictly as a prescription only agent.

Ciprofloxacin is categorized as a second-generation fluoroquinolone and is entirely produced through chemical synthesis. Its designation as a broad-spectrum antimicrobial agent underscores its capacity to target a diverse range of bacterial types. Popular brands containing the same Ciprofloxacin formulation include Cipro and Ciproxin.


How Flociprin Works: Its Bactericidal Purpose

The general purpose of Flociprin is to resolve the underlying infection by eliminating the responsible bacteria through a process called bactericidal action. This killing effect is achieved by the drug’s highly targeted ability to disrupt bacterial DNA processes.

Ciprofloxacin works by inhibiting two crucial enzymes within the bacterial cell: DNA gyrase and Topoisomerase IV. This specific dual-enzyme inhibition causes the bacterial cell to be unable to replicate or repair its genetic material. This specialized, fundamental mechanism provides a means of reducing the bacterial population and controlling the infection.


Flociprin Forms and Types (Oral, Topical, and Systemic)

Flociprin is manufactured in several pharmaceutical preparations to ensure the active ingredient can be delivered appropriately to various infection sites. The main dosage form(s) include oral tablets (immediate and extended-release), a liquid oral suspension, and a solution for intravenous infusion for internal use.

This variety allows Flociprin to be used for both systemic treatment, where the drug is circulated throughout the body, and topical treatment. For infections localized to the eyes or ears, the drug is formulated into specific eye drops (ophthalmic solution) and ear drops (otic solution), enabling direct and concentrated administration to the affected area.

Regulatory References

  1. Ciprofloxacin NIH Profile

What side effects are possible with Flociprin?

Possible Side Effects and Safety Information

Flociprin's safety profile is documented by regulatory authorities, classifying adverse reactions by frequency and physiological system. The most common side effects are typically related to the gastrointestinal system, often involving nausea and diarrhea. Reactions classified as uncommon include vomiting, abdominal pain, headache, and dizziness.

Serious Adverse Reactions

The regulatory labeling for Ciprofloxacin highlights specific serious adverse reactions. These include a risk of tendonitis and tendon rupture, which can occur during or several months after treatment completion. Other serious risks involve the Nervous System Disorders, such as peripheral neuropathy (which can be rapid in onset and potentially irreversible), seizures, and psychotic reactions. The safety profile also includes the risk of severe hypersensitivity reactions and an elevated risk of aortic aneurysm and dissection.

Safety Considerations for Specific Populations

Official documents detail specific safety notes for certain patient groups. Older adults are noted to have an increased risk of tendon rupture. For pediatric patients, the use of Flociprin is generally restricted due to the documented risk of joint damage (arthropathy). Furthermore, the medicine may exacerbate muscle weakness in individuals with myasthenia gravis, and patients should be advised to avoid undue exposure to direct sunlight due to the risk of photosensitivity.

Overdose and Emergency Response

Overdose and When to Seek Help

Flociprin is a fluoroquinolone antibiotic. Taking an excessive amount of this medication requires immediate medical evaluation, as a massive acute overdose can lead to serious systemic effects.

Overdose Clinical Manifestations

Symptoms that have been reported following a massive acute overdose primarily involve the renal and central nervous systems:

  • Renal Toxicity: Acute renal failure, reversible renal impairment, and the formation of crystals in the urine (crystalluria) have been observed.
  • Gastrointestinal: Erosions of the gastrointestinal lining.
  • Central Nervous System (CNS): Dizziness, confusion, tremor, and headache.

Emergency Actions

In the event of a suspected or confirmed overdose, the patient should be monitored closely and given supportive treatment by medical professionals. To help prevent crystalluria, medical personnel will ensure the patient is well-hydrated. Treatments like gastric lavage may be considered. Hemodialysis or peritoneal dialysis are not effective for removing a significant amount of the drug from the body.

When to Seek Immediate Medical Help

If you believe you or someone else has taken too much Flociprin, seek emergency medical attention or call a Poison Control Centre immediately. Do not wait for symptoms to appear. Urgent medical care is essential for assessment and supportive management of potential renal complications.

Therapeutic Uses of Flociprin

What Flociprin Treats: Main Uses and Benefits

Flociprin, which contains the active ingredient ciprofloxacin, is a prescription antibiotic primarily used to manage a wide array of bacterial infections. Its use is directed toward helping manage the underlying infection. The scope of its applications covers specific indications for which the medication has been evaluated and approved for clinical use.

The medicine is indicated for use in the management of specific infections, including urinary tract infections (UTIs), certain respiratory tract infections (such as pneumonia), skin and soft tissue infections, and bone and joint infections. Ciprofloxacin is used when clinical circumstances warrant its selection based on its antibacterial profile.

Quick Fact: Management of the Underlying Bacterial Infection

Eligibility and Restrictions for Use

Flociprin, which contains the fluoroquinolone antibiotic Ciprofloxacin, is subject to specific population eligibility rules established by regulatory authorities. These rules define who is approved to use the medicine and who must not use it.

Contraindicated Populations (Must Not Use)

Flociprin is formally contraindicated and must not be used in:

  • Patients with a known hypersensitivity or allergic reaction to Ciprofloxacin or any other quinolone/fluoroquinolone antibiotic.
  • Patients who are concurrently taking the drug Tizanidine.
  • Patients with a known history of Myasthenia Gravis.

Age-Related and Conditional Eligibility

  • Adults (ge 18 years of age): Are the primary population for most approved uses.
  • Pediatric Patients: General use is restricted due to the risk of joint-related disorders. Use is limited to specific severe infections like Inhalational Anthrax or Plague, or Complicated Urinary Tract Infections when alternatives are unavailable.
  • Renal Impairment: Patients with reduced kidney function require a dosage adjustment to remain eligible for treatment.
  • Older Adults (ge 60 years of age): Are identified as being at an increased risk for severe tendon disorders.

Pregnancy and Lactation

  • Pregnancy: Safety is not fully established. Use is reserved only for circumstances where the potential benefit justifies the potential risk.
  • Lactation: Breastfeeding is not recommended during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Flociprin’s official interaction profile is defined by pharmacokinetic changes, specific prohibitions, and mandatory timing constraints documented in regulatory labeling.

Interaction Scope

Category Description Entities / Restrictions
Contraindicated Combination Co-administration is formally prohibited by regulatory authorities. Tizanidine is strictly contraindicated.
Pharmacokinetic Inhibition Flociprin is documented as an inhibitor of the enzyme CYP1A2 metabolism pathway. This can increase the plasma concentrations of co-administered drugs metabolized by CYP1A2, such as Theophylline and Caffeine.
Pharmacodynamic Potentiation Combined effects that increase toxicity risk. Monitoring of INR is required when co-administered with Warfarin due to enhancement of the anticoagulant effect. Caution is also noted with Antidiabetic Agents due to risk of blood glucose disturbances.
Absorption Chelation Absorption of oral Flociprin is significantly reduced due to binding. Multivalent Cation-Containing Products (e.g., antacids, iron supplements, calcium-fortified juices) must be separated.

Timing and Separation Requirements

To prevent chelation-based absorption failure, oral Flociprin tablets must be administered at least 2 hours before or 6 hours after any multivalent cation products. Regulatory documents also note that administration with dairy products or calcium-fortified juices alone should be avoided due to decreased absorption. The interaction profile highlights that co-administration with Probenecid reduces Flociprin's renal clearance, leading to increased systemic concentration. The overall structure of the regulatory profile necessitates strict adherence to these timing and prohibition rules.

Mechanism of Action

Flociprin's action disrupts critical biological processes of the bacterial cell through a targeted, multi-stage mechanism.

Targeting Bacterial DNA Gyrase and Topoisomerase IV

The primary mechanism involves the inhibition of two key bacterial enzymes: DNA Gyrase and Topoisomerase IV. Flociprin acts as a catalytic poison, trapping these enzymes while they are bound to the bacterial DNA. This dual molecular targeting initiates a cascade leading to cell death, preventing the cell from performing vital genetic tasks like replication and chromosome separation.

The Bactericidal Cascade and DNA Damage

The stabilization of the enzyme-DNA complex leads to the rapid accumulation of extensive DNA double-strand breaks (DSBs). This molecular damage forces the bacterial cell to activate a stress response, resulting in bactericidal action. The physiological consequence of this mechanism is the elimination (killing) of the susceptible bacterial population.

Mechanistic Constraints and Evasion

The functional capacity of this mechanism is constrained by the bacterium's ability to resist or evade the action. The mechanism can be weakened if mutations occur in the genes for DNA Gyrase or Topoisomerase IV (gyrA), reducing the drug's binding affinity. Additionally, changes to the bacterial membrane that restrict drug access can limit the mechanism's functional ability to reach its molecular targets.

Dosage and Administration Information

Administration Instructions

The following rules define the use of Flociprin (ciprofloxacin), encompassing both oral and intravenous administration. Adhering to the prescribed length of time is mandatory, even if symptoms improve.

Dosing and Administration

Administration Detail General Instruction
Route of Administration Oral (tablet, extended-release tablet, or suspension) or Intravenous (IV) infusion.
Dosing Frequency Typically administered every 12 hours (twice daily) or every 24 hours (once daily) depending on the form and prescribed dose.
Tablets Swallow immediate-release and extended-release tablets whole; do not crush, split, or chew.
Oral Suspension Shake vigorously for at least 15 seconds just before each use. Do not administer through a feeding tube.
IV Infusion Must be administered slowly over a period of 60 minutes.

Timing and Special Conditions

  • Food: Oral tablets may be taken with or without food. To ensure optimal absorption, the medicine should not be taken alone with dairy products (e.g., milk, yogurt) or calcium-fortified juices, but may be taken with a meal that contains these products.
  • Other Medications: Separate the dose of Flociprin by at least 2 hours before or 6 hours after taking multivalent cation-containing products, such as magnesium/aluminum antacids, sucralfate, iron supplements, or zinc supplements, as these can significantly reduce drug absorption.
  • Hydration: Patients should ensure adequate hydration and drink plenty of fluids while using this medicine.
  • Missed Dose: If a dose is missed, take it as soon as it is remembered. However, if the next dose is due in less than 6 hours (for immediate-release) or less than 8 hours (for extended-release), skip the missed dose and resume the normal schedule. Do not take two doses at the same time.

Recent Clinical Evidence

Flociprin: Recent Clinical Evidence

Flociprin was studied in the context of various bacterial infections across different parts of the body. The research base includes large-scale clinical trials designed to understand the outcomes measured in specific patient groups under controlled conditions. The studies primarily examined the clearance of the bacteria and the resolution of infection-related symptoms.


Evidence for Common Systemic and Specialized Infections

The main research exploring Flociprin for urinary tract and lower respiratory tract infections comes from Randomized Controlled Trials (RCTs). These studies compared Flociprin against other treatments, monitoring measured outcomes like bacteriological clearance and clinical cure. Findings describe patterns related to how symptoms changed in the observed populations. Flociprin was also evaluated in patient groups with deep-seated infections like those affecting bone and joints, requiring Controlled Clinical Trials with extended follow-up. For rare public health scenarios, such as Anthrax post-exposure prophylaxis, the regulatory process accepted data derived from animal models related to effectiveness, due to the critical nature of the conditions.


Evidence Gaps and Outcomes in Special Populations

The research landscape includes studies dedicated to children (pediatric patients), primarily for complicated urinary tract infections, designed to track long-term patterns. Research also explored the medicine's use in older adults. However, data for certain groups remain insufficient, including high-risk patients and pregnancy-related populations, where ethical constraints often limit the ability to conduct Randomized Controlled Trials. The long-term outcomes are not fully established for many acute conditions due to limited trial follow-up. Furthermore, bacterial resistance to the medicine was observed in some studies, a trend relevant to the broader research landscape.

Key Studies & References

  1. WHO Model List of Essential Medicines
  2. Ciprofloxacin: Clinical Pharmacology and Use in Pediatric Patients

Frequently Asked Questions (FAQ)

Common questions about Flociprin (FAQ)


Q: How is Flociprin different from other similar common treatments?

Flociprin is classified as a fluoroquinolone antibiotic, a group of medicines that are chemically made. Official information describes its difference through its unique way of working, which involves disrupting the life cycle of bacteria by inhibiting two specific bacterial enzymes: DNA gyrase and Topoisomerase IV. This specific dual mechanism distinguishes it from other antibiotic treatments that rely on different biological targets.


Q: How quickly can I expect Flociprin to start working?

While the medicine begins its action against bacteria shortly after the very first dose, regulatory patient information indicates that a patient may begin to notice a change in their symptoms after a few days, or potentially longer. The time it takes to see improvement is highly dependent on the type and severity of the specific infection being treated.


Q: Are there any long-term effects associated with Flociprin use?

Regulatory documents indicate that in rare cases, some serious side effects associated with Flociprin, such as tendonitis, nerve damage (peripheral neuropathy), or effects on the central nervous system, are described as having the potential to be persistent and disabling in some rare instances. These effects are documented as sometimes occurring during treatment or even months after the treatment course has been completed.


Q: Can Flociprin be used if I have kidney issues?

Official guidelines state that Flociprin is generally eligible for use in individuals with reduced kidney function, also known as renal impairment. For patients with reduced kidney function, official guidelines indicate that a change in the prescribed dose or frequency may be necessary to manage drug levels and prevent potential accumulation.


Q: Does Flociprin cause any issues with birth control pills?

Official safety sources note that some antibiotics, including Flociprin, may potentially lower the effectiveness of hormonal birth control (oral contraceptives) in some individuals. This interaction could potentially increase the risk for an unintended pregnancy or cause breakthrough bleeding. For specific advice regarding birth control methods, a healthcare provider can offer relevant guidance.


Q: Is Flociprin known to affect mood or cause anxiety?

Yes, regulatory labeling documents that Flociprin can cause side effects related to the central nervous system. These documented reactions include anxiety, confusion, depression, and restlessness. In rare instances, more severe effects like psychotic reactions or suicidal thoughts have been reported. If symptoms of concern occur, the regulatory labeling advises contacting a healthcare provider immediately.


Q: Does Flociprin contain any common allergens like gluten or lactose?

Official product labeling lists all inactive ingredients used in the formulation of Flociprin, which typically includes binding agents like microcrystalline cellulose and magnesium stearate. The full list of inactive ingredients, which details every component, is provided in the product label for reference regarding potential sensitivities like gluten-containing compounds or lactose.


Q: Is it possible to become resistant to the effects of Flociprin over time?

Official warnings state that the inappropriate use of Flociprin, such as not completing the full prescribed treatment course, can lead to the development of bacterial resistance. This means the bacteria that caused the original infection may develop resistance, which is a documented risk of non-adherence to the full prescribed course.


Q: Why is Flociprin sometimes prescribed instead of alternatives?

Flociprin is designated as a broad-spectrum antibiotic, meaning it targets a wide variety of bacterial strains. Official indications show it is reserved for specific severe or complicated bacterial infections where its broad spectrum of activity against a diverse range of bacterial strains may be appropriate.


Q: Can Flociprin affect my ability to drive or operate machinery?

Regulatory safety information warns that Flociprin has the potential to cause side effects that could affect a patient's ability to drive or operate complex machinery. Potential effects include dizziness, visual disturbances, and confusion. Patients are generally advised to be aware of how the medicine affects them before engaging in activities that require full mental alertness.


Q: Is the list of side effects in the official documents complete?

The list of side effects provided in official drug labeling is compiled from controlled clinical trials and ongoing safety reports (post-marketing surveillance). Regulatory documents explicitly note that additional adverse reactions are reported voluntarily after the medicine is on the market and may not always represent a complete, exhaustive list of every possible reaction.


Q: What is the recommended timeframe to wait after stopping Flociprin before feeling 'normal'?

Pharmacokinetic data indicates that Flociprin has an elimination half-life of approximately 4 hours, meaning the drug is generally cleared from the bloodstream within about 20 to 24 hours after the final dose in most people. The time required for an individual's complete recovery from an infection, which affects overall well-being, is highly variable and depends on the specific condition being treated.


Q: Are there specific symptoms that indicate Flociprin is not working?

Official patient guidance suggests that symptoms related to the infection should begin to improve within a few days of starting Flociprin. If the symptoms fail to resolve, or if they appear to worsen after beginning the medicine, regulatory documentation notes that such an outcome may be associated with the drug not being active against the bacteria causing the infection.


Q: What does official data say about Flociprin and alcohol consumption?

Official regulatory labels do not formally prohibit moderate alcohol consumption while taking Flociprin. However, general patient information often advises that consuming alcohol may intensify some of the drug's common central nervous system or gastrointestinal side effects, such as dizziness or nausea.


Q: Is Flociprin available over-the-counter in any country?

In alignment with the World Health Organization (WHO) and major governmental drug authorities, Flociprin (Ciprofloxacin) is consistently classified as a prescription-only medicine. This is due to its potent antibiotic properties and the need for medical oversight to manage the risk of serious side effects and prevent antibiotic resistance.


Q: Are there common user complaints about the taste or texture of Flociprin?

Regulatory documents for the liquid oral suspension form of Flociprin note that the product is manufactured with a specific flavor (often strawberry) to improve its palatability. This indicates that manufacturers are aware of potential taste concerns for patients who use the liquid preparation.


Q: What are the official guidelines regarding Flociprin and sunlight exposure?

Official warnings describe that patients should limit or avoid undue exposure to direct sunlight and UV light (e.g., from tanning beds) while undergoing treatment. This is because Flociprin is known to increase the risk of a severe sunburn reaction called photosensitivity.


Q: Is Flociprin known to interact with herbal supplements?

Regulatory documents explicitly warn about severe interactions with any supplements containing multivalent cations (minerals like iron, calcium, or zinc) due to impaired drug absorption. For the majority of other non-mineral herbal or complementary medicines, regulatory bodies generally state that there is insufficient data to confirm or deny potential interactions.


Q: What does the research say about stopping Flociprin suddenly?

Official instructions emphasize that patients should not stop taking the medicine abruptly, even if symptoms improve quickly, to ensure the full treatment effect. Regulatory documents state that treatment must be completed as prescribed, except in cases of serious adverse reactions, where the regulatory guidelines advise immediate communication with a healthcare professional.


Q: How long does Flociprin stay in the system after the last intake?

Based on pharmacokinetic data, Flociprin has an estimated serum half-life of approximately 4 hours. This means that, assuming normal kidney function, the drug is considered to be virtually cleared from the body (eliminated) within approximately 20 to 24 hours after the last dose is taken.


Q: What are the reported rates of the most common side effects?

Official product labeling provides clear frequency categories for side effects, which are determined by data from clinical trials and safety surveillance. These categories use terms like 'Common' (e.g., affecting 1 in 10 to 1 in 100 people) and 'Uncommon' (e.g., affecting 1 in 100 to 1 in 1,000 people) to report how often a reaction occurred in tested populations.


Q: Do official materials clarify if Flociprin affects fertility?

Regulatory-sourced patient information often includes a statement that there is no clear evidence from official studies or surveillance to suggest that Flociprin significantly reduces or impairs fertility in either men or women. Patients who are planning a pregnancy are advised to consult with their doctor.


Q: What are the general expectations for a patient's outcome when taking Flociprin?

Official indications describe the expected patient outcome as the resolution of the underlying infection through the drug's effect of bacteriological clearance (killing the susceptible bacteria). This process is intended to support the resolution or improvement of the clinical symptoms caused by the infection.


Q: Has Flociprin been studied for any other potential uses besides its main indications?

While the drug is primarily approved and studied for its main uses (like complicated urinary tract infections), research evidence also shows it has been explored and evaluated for more specialized and severe infections. Examples include deep-seated conditions like bone and joint infections, as well as specific pediatric uses.


Q: Why does Flociprin have certain restrictions for people with liver issues?

Official warnings are in place because Flociprin has been linked, in rare instances, to drug-induced liver injury (DILI), including severe or fatal cases of hepatic failure. Regulatory documents advise monitoring liver function tests and immediately discontinuing the drug if any signs of liver damage, such as jaundice (yellowing of the skin), appear.

How should Flociprin be stored and disposed of?

The storage and disposal requirements for Flociprin (Ciprofloxacin) are strictly governed by regulatory documentation to preserve drug stability.

Storage Conditions Tablets / Reconstituted Oral Suspension Intravenous Solution
Temperature Store below 30 C (86 F) Store between 20 C and 25 C (68 F and 77 F)
Freezing Constraint Do not freeze Do not freeze

Ciprofloxacin tablets must be stored in a tight container and protected from intense UV light. The reconstituted oral suspension has an in-use stability of 14 days and must be discarded after this period. The medicine must be kept out of the sight and reach of children.

Official disposal protocols prioritize using a drug take-back program. If a take-back option is unavailable, the drug should be mixed with an undesirable substance, placed in a sealed container, and thrown into the household trash; the product must not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flociprin found in:

A-Z Index: